Dr. VK Gadi & Dr. Jason Mouabbi – HER2 Positive & HER2 Low Updates and Therapies

Join Dr. VK Gadi and Dr. Jason Mouabbi at a recent conference for their discussion around the changing function of antibody-drug conjugates (ADCs) such as T-DXd (trastuzumab deruxtecan) in treating HER2-positive breast cancer, especially in patients with central nervous system (CNS) metastases. The talk hinges on the historical use of tiny compounds like tucatinib to ensure they’re able to pass the blood-brain barrier. New research, however, challenges the conventional wisdom on treatment restrictions by showing that ADCs might also be useful in this environment.

Dr. Mouabbi offered a real-world illustration of T-DXd’s transforming power by sharing a clinical case whereby it produced amazing regression of both visceral and central nervous system disorders. Data from studies like as DESTINY-Breast04 and the forthcoming DB12 study, which concentrates on patients with untreated or stable brain metastases, could provide vital direction on T-DXd’s efficacy in CNS care. In line with the encouraging findings observed in clinical practice, this trial seeks to confirm T-DXd’s influence on brain metastases.

The discussion also touches on the need for closely monitoring patients, especially for possible side effects including interstitial lung disease (ILD), with doctors using routine CT imaging and pulmonary function testing. Dr. Mouabbi underlined that novel treatments such as T-DXd represent a turning point in the field and give patients with metastatic breast cancer hitherto unheard-of hope.

You can watch the full conversation between Dr. Gadi and Dr. Mouabbi below to hear more of their experience and analysis of how ADCs are changing HER2-positive breast cancer treatment, therefore offering patients with advanced illness more focused and efficient choices.